AptarGroup to Announce Q4 Earnings Amid Cautious Market Outlook
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 23 2026
0mins
Source: seekingalpha
AptarGroup (ATR) shares fell 5.01% as the stock crossed below the 5-day SMA, reflecting broader market weakness with the Nasdaq-100 down 1.22% and the S&P 500 down 1.07%.
The company is set to release its Q4 earnings on February 5th, with a consensus EPS estimate of $1.23, indicating a 17.4% year-over-year decline. Revenue is projected at $878.58 million, suggesting a 3.6% year-over-year growth. However, the lack of upward revisions for EPS estimates and multiple downward adjustments for revenue estimates reflect a cautious market outlook, which may impact investor confidence.
As AptarGroup prepares for its earnings announcement, the mixed expectations could lead to volatility in its stock price. The company's historical performance shows it has beaten EPS estimates 75% of the time, but challenges in revenue growth remain a concern.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ATR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ATR
Wall Street analysts forecast ATR stock price to rise
4 Analyst Rating
1 Buy
3 Hold
0 Sell
Hold
Current: 116.580
Low
133.00
Averages
145.33
High
156.00
Current: 116.580
Low
133.00
Averages
145.33
High
156.00
About ATR
AptarGroup, Inc. is engaged in the design and manufacturing of drug and consumer product dosing, dispensing, and protection technologies. The Company serves diversified end markets including pharmaceutical, fragrance, facial skincare, color cosmetics, food, beverage, personal care, and home care. It also manufactures and sells elastomeric primary packaging components. It operates through three segments, which include the Pharma segment, Beauty segment, and Closures segment. The Pharma segment is a supplier of nasal drug delivery spray pumps and metered dose inhaler valves (MDIs) to the pharmaceutical and health care markets worldwide. The Beauty segment sells pumps, airless systems and valves to the fragrance, color cosmetics, facial skincare, personal care, and home care markets. The Closures segment includes dispensing and non-dispensing solutions that enable product delivery without removal of the cap and are used across multiple consumer end markets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Aptar Recognized as CDP Supplier Engagement Leader for Sixth Consecutive Year
- Sustainability Strategy: Aptar achieved an 'A' score in the 2025 CDP reporting cycle, being recognized as a Supplier Engagement Leader for the sixth consecutive year, highlighting its leadership in climate change and emissions reduction, which further drives the company's sustainable development in the global supply chain.
- Supply Chain Collaboration: With over 90% of Aptar's emissions classified as Scope 3, and more than 80% linked to purchased goods and services, particularly raw materials, the company demonstrates its commitment to promoting lower-carbon alternatives and advancing circular economy initiatives.
- Innovation Exchange Platform: Through structured forums like the Aptar Global Supplier Summit, Aptar has strengthened interactions with suppliers, facilitating innovation exchanges and aligning sustainability priorities, aiming to enhance supply chain transparency and performance.
- Environmental Data Sharing: Aptar expects suppliers to share environmental data and participate in assessments, driving initiatives focused on materials, emissions reduction, and responsible sourcing, ensuring alignment between supply chain sustainability and corporate strategic goals.
See More
AptarGroup Announces Upcoming Investor Conference Schedule
- Investor Conference Schedule: AptarGroup will present at the Jefferies Global Healthcare Conference in New York on June 3, 2026, with CFO Vanessa Kanu speaking at 12:45 PM EST, highlighting the company's leadership in drug delivery and consumer products.
- Industry Engagement Opportunity: Following this, AptarGroup will also participate in the Wells Fargo Industrials and Materials Conference in Chicago on June 9, 2026, where Kanu will present at 1:45 PM EST, further enhancing investor relations.
- Live Webcast and Materials: During the conferences, AptarGroup will provide a live audio webcast and presentation materials on its website's
See More
Aptar and Clarins Win 2026 DIELINE Award for Sustainable Design
- Sustainable Design Innovation: The custom reloadable airless packaging solution developed by Aptar and Clarins reduces material impact by 73%, utilizing 50% less metal, 33% less plastic, and 29% less cardboard, significantly enhancing product sustainability and market competitiveness.
- Industry Recognition: The Clarins Total Eye Lift packaging solution received the Formes de Luxe Award in 2025 and was awarded First Place in the Sustainable Design category at the 2026 DIELINE Awards, highlighting its excellence in innovation and execution.
- Technological Advantage: Aptar's patented Gaïa airless technology combines a premium metal outer casing with plastic reloads, preserving luxury aesthetics while significantly reducing material usage, enhancing product circularity and consumer experience.
- Market Impact: This innovation not only elevates Clarins' market differentiation and brand equity but also demonstrates the compatibility of luxury and sustainability, driving progress in the high-end skincare market.
See More
AptarGroup Q1 2026 Earnings Call Insights
- Financial Performance Overview: AptarGroup reported an 11% increase in sales with flat core sales, achieving adjusted EBITDA of $189 million and an EBITDA margin of 19.2%, indicating that overall performance met expectations amid anticipated emergency medicine destocking.
- CEO Transition: Current CEO Stephan Tanda announced his retirement effective September 1, with Gael Touya set to take over, highlighting the company's stability and strategic continuity during leadership changes.
- Market Demand Dynamics: The Pharma segment continues to see growing demand in key areas such as GLP-1, biologics, and systemic nasal drug delivery, with prescription core sales down 10% but injectables core sales up 20%, reflecting a differentiated market trend.
- Future Outlook and Investment: Management guided for second quarter adjusted earnings per share between $1.32 and $1.40, while planning capital investments of $260 million to $280 million, demonstrating the company's confidence in future growth and commitment to ongoing investments.
See More
AptarGroup Reports Decline in Q1 Earnings
- Earnings Decline: AptarGroup's Q1 net income fell to $72.67 million, or $1.12 per share, down from $78.79 million and $1.17 per share last year, indicating profitability challenges for the company.
- Revenue Growth: Despite the earnings drop, the company reported a 10.8% increase in revenue to $982.86 million compared to $887.30 million last year, demonstrating strong sales performance.
- Adjusted Earnings: Excluding special items, AptarGroup's adjusted earnings were $77.20 million, or $1.19 per share, indicating stability in core operations despite the overall earnings decline.
- Future Guidance: The company provided Q2 EPS guidance of $1.32 to $1.40, reflecting management's cautiously optimistic outlook for future performance, which may attract investor interest.
See More
AptarGroup Q1 2026 Earnings Exceed Expectations
- Earnings Beat: AptarGroup reported a Q1 2026 non-GAAP EPS of $1.19, exceeding expectations by $0.04, indicating strong performance and improved profitability in the market.
- Significant Revenue Growth: The company achieved revenues of $982.9 million in Q1, reflecting a 10.8% year-over-year increase and surpassing market expectations by $26.96 million, demonstrating sustained growth in sales and market demand.
- Optimistic Outlook: Aptar anticipates adjusted EPS for Q2 2026 to be in the range of $1.32 to $1.40, reflecting confidence in future performance while assuming an effective tax rate between 22.5% and 24.5%.
- Exchange Rate Consideration: This earnings guidance is based on an exchange rate of 1.18 Euros to USD, highlighting the company's foreign exchange risk management strategy in its global operations.
See More
Aptar Recognized as CDP Supplier Engagement Leader for Sixth Consecutive Year
- Sustainability Strategy: Aptar achieved an 'A' score in the 2025 CDP reporting cycle, being recognized as a Supplier Engagement Leader for the sixth consecutive year, highlighting its leadership in climate change and emissions reduction, which further drives the company's sustainable development in the global supply chain.
- Supply Chain Collaboration: With over 90% of Aptar's emissions classified as Scope 3, and more than 80% linked to purchased goods and services, particularly raw materials, the company demonstrates its commitment to promoting lower-carbon alternatives and advancing circular economy initiatives.
- Innovation Exchange Platform: Through structured forums like the Aptar Global Supplier Summit, Aptar has strengthened interactions with suppliers, facilitating innovation exchanges and aligning sustainability priorities, aiming to enhance supply chain transparency and performance.
- Environmental Data Sharing: Aptar expects suppliers to share environmental data and participate in assessments, driving initiatives focused on materials, emissions reduction, and responsible sourcing, ensuring alignment between supply chain sustainability and corporate strategic goals.
See More
AptarGroup Announces Upcoming Investor Conference Schedule
- Investor Conference Schedule: AptarGroup will present at the Jefferies Global Healthcare Conference in New York on June 3, 2026, with CFO Vanessa Kanu speaking at 12:45 PM EST, highlighting the company's leadership in drug delivery and consumer products.
- Industry Engagement Opportunity: Following this, AptarGroup will also participate in the Wells Fargo Industrials and Materials Conference in Chicago on June 9, 2026, where Kanu will present at 1:45 PM EST, further enhancing investor relations.
- Live Webcast and Materials: During the conferences, AptarGroup will provide a live audio webcast and presentation materials on its website's
See More
Aptar and Clarins Win 2026 DIELINE Award for Sustainable Design
- Sustainable Design Innovation: The custom reloadable airless packaging solution developed by Aptar and Clarins reduces material impact by 73%, utilizing 50% less metal, 33% less plastic, and 29% less cardboard, significantly enhancing product sustainability and market competitiveness.
- Industry Recognition: The Clarins Total Eye Lift packaging solution received the Formes de Luxe Award in 2025 and was awarded First Place in the Sustainable Design category at the 2026 DIELINE Awards, highlighting its excellence in innovation and execution.
- Technological Advantage: Aptar's patented Gaïa airless technology combines a premium metal outer casing with plastic reloads, preserving luxury aesthetics while significantly reducing material usage, enhancing product circularity and consumer experience.
- Market Impact: This innovation not only elevates Clarins' market differentiation and brand equity but also demonstrates the compatibility of luxury and sustainability, driving progress in the high-end skincare market.
See More
AptarGroup Q1 2026 Earnings Call Insights
- Financial Performance Overview: AptarGroup reported an 11% increase in sales with flat core sales, achieving adjusted EBITDA of $189 million and an EBITDA margin of 19.2%, indicating that overall performance met expectations amid anticipated emergency medicine destocking.
- CEO Transition: Current CEO Stephan Tanda announced his retirement effective September 1, with Gael Touya set to take over, highlighting the company's stability and strategic continuity during leadership changes.
- Market Demand Dynamics: The Pharma segment continues to see growing demand in key areas such as GLP-1, biologics, and systemic nasal drug delivery, with prescription core sales down 10% but injectables core sales up 20%, reflecting a differentiated market trend.
- Future Outlook and Investment: Management guided for second quarter adjusted earnings per share between $1.32 and $1.40, while planning capital investments of $260 million to $280 million, demonstrating the company's confidence in future growth and commitment to ongoing investments.
See More
AptarGroup Reports Decline in Q1 Earnings
- Earnings Decline: AptarGroup's Q1 net income fell to $72.67 million, or $1.12 per share, down from $78.79 million and $1.17 per share last year, indicating profitability challenges for the company.
- Revenue Growth: Despite the earnings drop, the company reported a 10.8% increase in revenue to $982.86 million compared to $887.30 million last year, demonstrating strong sales performance.
- Adjusted Earnings: Excluding special items, AptarGroup's adjusted earnings were $77.20 million, or $1.19 per share, indicating stability in core operations despite the overall earnings decline.
- Future Guidance: The company provided Q2 EPS guidance of $1.32 to $1.40, reflecting management's cautiously optimistic outlook for future performance, which may attract investor interest.
See More
AptarGroup Q1 2026 Earnings Exceed Expectations
- Earnings Beat: AptarGroup reported a Q1 2026 non-GAAP EPS of $1.19, exceeding expectations by $0.04, indicating strong performance and improved profitability in the market.
- Significant Revenue Growth: The company achieved revenues of $982.9 million in Q1, reflecting a 10.8% year-over-year increase and surpassing market expectations by $26.96 million, demonstrating sustained growth in sales and market demand.
- Optimistic Outlook: Aptar anticipates adjusted EPS for Q2 2026 to be in the range of $1.32 to $1.40, reflecting confidence in future performance while assuming an effective tax rate between 22.5% and 24.5%.
- Exchange Rate Consideration: This earnings guidance is based on an exchange rate of 1.18 Euros to USD, highlighting the company's foreign exchange risk management strategy in its global operations.
See More
